Lauren Demino
Primary Care · Mineola, NYNPI 1760901730
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,151 of the $1,311 with a category attached, or 87.8%. 10 manufacturers reported payments, led by Galderma Laboratories, L.p. at 54.2% of the total. 2025 is the largest year on record at $715, 5.4 times the $132 reported in 2023.
Across 66 payments — averaging $19.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Galderma Laboratories, L.p.$711
- AbbVie$249
- Johnson & Johnson$162
- Cipher Pharmaceuticals US LLC$47
- Arcutis Biotherapeutics, Inc.$44
- Botanix SB Inc$41
- plus $57 from 4 others
What the payments were for
- Food & beverage$1,15188%
- Education$16012%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Galderma Laboratories, L.p. | 46 | $711 |
| AbbVie | 8 | $249 |
| Johnson & Johnson | 3 | $162 |
| Cipher Pharmaceuticals US LLC | 1 | $47 |
| Arcutis Biotherapeutics, Inc. | 2 | $44 |
| Botanix SB Inc | 2 | $41 |
| Scpharmaceuticals Inc. | 1 | $19 |
| Pfizer | 1 | $15 |
| Strata Skin Sciences, Inc. | 1 | $15 |
| Organon | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$125
How this compares
$1,311 in reported general payments places this provider in the 75th percentile of 239 primary care providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tacrolimus | 71 | $11,208 |
| Dapsone | 11 | $3,433 |
| Fluorouracil | 28 | $1,463 |
| Ketoconazole | 70 | $1,078 |
| Clobetasol Propionate | 23 | $1,023 |
| Ciclopirox | 27 | $623 |
| Triamcinolone Acetonide | 43 | $427 |
| Econazole Nitrate | 13 | $379 |
| Mupirocin | 32 | $252 |
| Mometasone Furoate | 13 | $224 |
Paid to pharmacies, not to this prescriber.
Other primary care in Mineola
- Dorothy KleinertNew York$27K
- Stephanie KhanForest Hills$16K
- Albert MarcanoJackson Heights$15K
- Elizabeth GattmanJamestown$10K
- Vanessa WangFlushing$10K
- Elizabeth SmithWaterloo$9K
- Eric RodriguezSyracuse$7K
- Natalie Sommerville-BrooksBrooklyn$6K
- Lisa PlanetaNew York$6K
- Pao-Ju TsengFlushing$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.